ATTB.F Stock Overview
Operates as a life sciences and biotechnology company in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Abattis Bioceuticals Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.00013 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 33 Year Change | -99.00% |
| 5 Year Change | -99.98% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| ATTB.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 3.4% | 1.6% |
| 1Y | 0% | 14.2% | 32.3% |
Return vs Industry: ATTB.F underperformed the US Pharmaceuticals industry which returned 14.2% over the past year.
Return vs Market: ATTB.F underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| ATTB.F volatility | |
|---|---|
| ATTB.F Average Weekly Movement | 3,797.8% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ATTB.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ATTB.F's weekly volatility has increased from 3416% to 3798% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | n/a | Rob Abenante | www.abattis.com |
Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cannabis industry.
Abattis Bioceuticals Corp. Fundamentals Summary
| ATTB.F fundamental statistics | |
|---|---|
| Market cap | US$476.00 |
| Earnings (TTM) | -US$2.17m |
| Revenue (TTM) | US$254.64k |
0.0x
P/S Ratio0.0x
P/E RatioIs ATTB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATTB.F income statement (TTM) | |
|---|---|
| Revenue | CA$356.88k |
| Cost of Revenue | CA$115.54k |
| Gross Profit | CA$241.34k |
| Other Expenses | CA$3.28m |
| Earnings | -CA$3.04m |
Last Reported Earnings
Sep 30, 2019
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ATTB.F perform over the long term?
See historical performance and comparison